Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Assets (2019 - 2025)

IDEAYA Biosciences' Non-Current Assets history spans 7 years, with the latest figure at $442.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 1.89% year-over-year to $442.6 million; the TTM value through Dec 2025 reached $1.6 billion, up 25.41%, while the annual FY2025 figure was $442.6 million, 1.89% up from the prior year.
  • Non-Current Assets for Q4 2025 was $442.6 million at IDEAYA Biosciences, up from $382.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $442.6 million in Q4 2025 and bottomed at $17.5 million in Q3 2022.
  • The 5-year median for Non-Current Assets is $123.5 million (2021), against an average of $178.7 million.
  • The largest annual shift saw Non-Current Assets surged 1248.83% in 2021 before it tumbled 86.61% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $130.4 million in 2021, then crashed by 86.56% to $17.5 million in 2022, then surged by 566.19% to $116.7 million in 2023, then skyrocketed by 272.27% to $434.4 million in 2024, then increased by 1.89% to $442.6 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Non-Current Assets are $442.6 million (Q4 2025), $382.5 million (Q3 2025), and $355.7 million (Q2 2025).